Detailed Information on Publication Record
2014
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
SLAVÍČEK, Lubomír, Tomáš PAVLÍK, Jiří TOMÁŠEK, Zbyněk BORTLÍČEK, Tomáš BÜCHLER et. al.Basic information
Original name
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
Authors
SLAVÍČEK, Lubomír (203 Czech Republic), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Jiří TOMÁŠEK (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Tomáš BÜCHLER (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Rostislav VYZULA (203 Czech Republic), Jana PRAUSOVÁ (203 Czech Republic), Jindřich FÍNEK (203 Czech Republic), Ondřej MÁJEK (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution)
Edition
BMC Gastroenterology, London, BioMed Central, 2014, 1471-230X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.365
RIV identification code
RIV/00216224:14110/14:00075327
Organization unit
Faculty of Medicine
UT WoS
000334417600002
Keywords in English
Anti-angiogenic therapy; Chemotherapy; Elderly patients; Overall survival; Progression-free survival
Tags
Tags
International impact, Reviewed
Změněno: 24/4/2015 12:59, Soňa Böhmová
Abstract
V originále
V rámci práce bylo sledováno 3187 pacientů s mCRC léčených bevacizumabem v 1. linii z českého národního registru pacientů s mCRC. Cílem bylo porovnat účinnost a bezpečnost léčby v různých věkových kategoriích.